VKTX
https://ir.vikingtherapeutics.com/2024-06-04-Viking-Therapeutics-Announces-Positive-52-Week-Histologic-Data-from-Phase-2b-VOYAGE-Study-of-VK2809-in-Patients-with-Biopsy-Confirmed-Non-Alcoholic-Steatohepatitis-NASH

SKYE
https://skyebioscience.com/clinical-trials/
https://skyebioscience.com/technology/
https://ir.skyebioscience.com/news-events/press-releases
https://d1io3yog0oux5.cloudfront.net/_e523f68ebe33459e527d7435a5373ac7/skyebioscience/db/781/7008/pdf/240601_SKYE_Investor+Presentation.pdf
https://opco2.bluematrix.com/sellside/EmailDocViewer?mime=pdf&co=Oppenheimer2&id=replaceme@bluematrix.com&source=mail&encrypt=497a1b6c-a959-49d0-80d2-1cc1845146f3
Additional opco report pdf published May 13, 2024
